← Eichor
Condition: Pathological Complete Response Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Pathological Complete Response

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia
Phase 1 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06245746Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06939127Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Phase 2 · 1 location(s) · Dallas VA Medical Center · NCT04018872Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immun
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06694454TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemo
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07330037Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1
Phase 2 · 1 location(s) · Ruijin Hospital · NCT06718244Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC
Phase N/A · 6 location(s) · University Medical Center Groningen · NCT06111807Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC
Phase 2 · 1 location(s) · Henan Cancer Hospital · NCT05918328A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Parti
Phase 3 · 267 location(s) · Merck Sharp & Dohme LLC · NCT06312137Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gast
Phase 2 · 1 location(s) · Peking University People's Hospital · NCT07586813Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC
NA · 1 location(s) · Yale University · NCT07066189Watch and Wait in PD-1 Monoclonal Antibody Treated dMMR/MSI-H Distal Rectal Cancer
NA · 1 location(s) · Sixth Affiliated Hospital, Sun Yat-sen University · NCT04643041LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer
Phase 2 · 10 location(s) · Universitaire Ziekenhuizen KU Leuven · NCT0683195540.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
Phase 3 · 15 location(s) · Ming-Yuan Chen · NCT07328854Monitoring Response to NAC and Prediction of pCR in Breast Cancer Patients Using Optical Imaging
NA · 1 location(s) · IRCCS San Raffaele · NCT04767659Relugolix + Enzalutamide Study in High-Risk Prostate Cancer
Phase 1 · 1 location(s) · University of Oklahoma · NCT06130995The Prognostic Value of the Degree of Pathological Response of Induction Chemotherapy for NPC
Phase N/A · 1 location(s) · Jiangxi Provincial Cancer Hospital · NCT06182657Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）
Phase 2 · 1 location(s) · The Affiliated Hospital of Qingdao University · NCT06647680Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinom
Phase 3 · 12 location(s) · Ming-Yuan Chen · NCT07328841Vabb After Neoadjuvant Therapy to Avoid Surgery-pCR to Avoid Breast Surgery
NA · 2 location(s) · European Institute of Oncology · NCT06281210Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
Phase 2 · 103 location(s) · Novartis Pharmaceuticals · NCT05268289Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas
NA · 16 location(s) · Centre Leon Berard · NCT04055220Comparing Post-Transplant Cyclophosphamide As GVHD Prophylaxis to Standard of Care for Acute Leukemia Patients
Phase 3 · 1 location(s) · King Faisal Specialist Hospital & Research Center · NCT04314219Improving Response to Chemotherapy by Adding Physical Exercise in the Neoadjuvant Setting of Breast Cancer Patients
NA · 1 location(s) · University Institute of Maia · NCT05976815Single-dose Preoperative Partial Breast Irradiation in Low-risk Breast Cancer Patients
NA · 7 location(s) · Amsterdam UMC, location VUmc · NCT05350722DESCARTES: De-ESCAlation of RadioTherapy in Patients With Pathologic Complete rESponse to Neoadjuvant Systemic Therapy
NA · 1 location(s) · The Netherlands Cancer Institute · NCT05416164Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell Carcinoma
Phase 2 · 1 location(s) · National Taiwan University Hospital · NCT06764355I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Phase 2 · 42 location(s) · QuantumLeap Healthcare Collaborative · NCT01042379Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT07407920Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple
Phase 2 · 1 location(s) · Shandong Cancer Hospital and Institute · NCT06802757
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.